Date of Report (Date of earliest event reported):
|
|
|
|
|
|
||||
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
||||
of Incorporation)
|
File Number)
|
Identification No.)
|
||||
|
|
|||||
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code
|
(
|
Not Applicable
|
(Former Name or Former Address, if Changed Since Last Report)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange on
which registered |
|
|
|
|
|
|
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
||
|
||
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
|
|||
By:
|
/s/ Kuk Hyoun Hwang | ||
Name:
|
Kuk Hyoun Hwang
|
||
Title:
|
Chief Executive Officer
|
1.
|
The name of the Corporation is Bellevue Life Sciences Acquisition Corp.
|
2.
|
The Corporation’s original certificate of incorporation was filed in the office of the Secretary of State of the State of Delaware on February 25, 2020 and
was subsequently amended by the filing of (i) a Certificate of Validation of Certificate of Amendment on January 20, 2021, (ii) an Amended and Restated Certificate of Incorporation on April 25, 2022, (iii) an Amended and Restated
Certificate of Incorporation on May 9, 2022, (iv) an Amended and Restated Certificate of Incorporation on February 13, 2023, and (v) a Certificate of Amendment to the Amended and Restated Certificate of Incorporation on November 9, 2023 (as
amended, the “Amended and Restated Certificate of Incorporation”).
|
3.
|
Article V. Section 6 of the Amended and Restated Certificate of Incorporation is hereby amended and restated in the entirety as follows:
|
4. |
Said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.
|
|
By: |
/s/ Kuk Hyoun Hwang |
|
Name: |
Kuk Hyoun Hwang |
|
Title: |
Chief Executive Officer |
Principal Amount: $75,000 | February 9, 2024 |
|
New York, New York |
|
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
|
||
|
|
|
|
|
|
|
|
By: |
/s/ Kuk Hyoun Hwang | ||
Name: |
Kuk Hyoun Hwang | ||
Title: |
Chief Executive Officer | ||
Email: |
[**]
|
By: |
/s/ Jun Chul Whang |
|
|
|
Name: |
Jun Chul Whang |
|
[**]
|
|||
[**]
|
|||
[**]
|
|||
|
|
|
-8?20$3;8T.P6BP^0"X99K>]9!:G
(Q[?F$>^33/5H%O?YB$["8]*(Y+ MPM7.;ZLG>%W]B\QC"?%M7L5>Z9XZSN5BBK?Z !2&0I3)-,NXN]RC'\"X!=AC M Q%B\@P@_W5NRN6:J+:7MUBM*D]END9*F!/Y#\#)M5-;K@>@;![%*
Q-1:RDL[A?@:Q3-3<[\X=IG!4#%
M#4[;'N/RSJ>^A%+'X5,^B?#CQ6[0HLX_1"5CJ>HVI[#YH/+D!W^5GB&J%]82
M]/B9S9YS#27'BP(G_E-H;#/